ArticleVeterinary dermatology2026
Incidence Rate of Otitis Externa Episodes in Atopic Dogs Is Reduced by a Therapeutic Diet in a 6-Month Randomised, Blinded, Controlled, Clinical Trial.
Article in Veterinary dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRecurrent otitis externa (OE) episodes commonly affect dogs with canine atopic dermatitis (cAD) despite ongoing cAD treatment.
objectiveTo determine if a therapeutic diet with active ingredients targeting the skin barrier and allergy pathways reduces the incidence rate of OE. ANIMALS, MATERIALS AND
methodsThirty-four client-owned dogs with active erythroceruminous OE + cAD (not necessarily active) were randomised to test (n = 16) or control diet (n = 18), fed for up to 6 months. Dogs had to be in remission by Month (M)1 after initial OE treatment. Outcomes included incidence rate (percentage of dogs with ≥ 1 OE episode), 0-3 Otitis Index Score (OTIS-3), cAD Extent and Severity Index, 4th iteration (CADESI-04), and medication score (medication required to control OE and/or cAD) at M3 and the end-point, defined as each dog's last on-study data.
resultsThe incidence rate was significantly lower in the test versus control group (25% vs. 61%, p < 0.01). OTIS-3 and CADESI-04 improved significantly between baseline and M3 in both groups (control: p = 0.003 and p < 0.001; test: each p = 0.001). Between M3 and the end-point, OTIS-3 and CADESI-04 rebounded significantly in the control (p = 0.025 and p = 0.026) and not in the test group (p = 0.139 and p = 0.909). CADESI improvement from baseline was maintained at the end-point in the test (p < 0.001) and not in the control group (p = 0.227). Medication score improved significantly throughout the diet duration in the test group (baseline to M3, M3 to end-point, and baseline to end-point) versus no improvements in the control group. CONCLUSION AND CLINICAL RELEVANCE: A therapeutic diet for cAD helped to sustain improvements in aural manifestations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.